MacroGenics (NASDAQ:MGNX) and Prana Biotechnology (NASDAQ:PRAN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.
This table compares MacroGenics and Prana Biotechnology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
MacroGenics has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500. Comparatively, Prana Biotechnology has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Institutional & Insider Ownership
90.5% of MacroGenics shares are owned by institutional investors. Comparatively, 3.6% of Prana Biotechnology shares are owned by institutional investors. 7.9% of MacroGenics shares are owned by insiders. Comparatively, 38.8% of Prana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares MacroGenics and Prana Biotechnology’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MacroGenics||$60.12 million||13.04||-$171.45 million||($4.19)||-3.83|
|Prana Biotechnology||$150,000.00||122.21||-$6.40 million||($0.70)||-2.94|
Prana Biotechnology has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Prana Biotechnology, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for MacroGenics and Prana Biotechnology, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MacroGenics currently has a consensus target price of $32.88, suggesting a potential upside of 104.73%. Given MacroGenics’ higher probable upside, research analysts clearly believe MacroGenics is more favorable than Prana Biotechnology.
Prana Biotechnology beats MacroGenics on 8 of the 13 factors compared between the two stocks.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
About Prana Biotechnology
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.